Business Context and Reporting Period
Atrium Therapeutics, Inc. (RNA) is a pre-clinical stage biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company became a standalone, publicly traded entity on February 26, 2026, following a spin-off from Avidity Biosciences, Inc. (now a subsidiary of Novartis AG). Prior to the spin-off, financial results were derived from Avidity's consolidated records.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $19.6 million | $1.6 million |
| Total Operating Expenses | $36.9 million | $9.0 million |
| Net Loss | $(16.6) million | $(7.4) million |
| Cash and Cash Equivalents (Ending) | $267.8 million | $0 |
| Stockholders' Equity | $234.1 million | $(62.7) million (Former Parent Deficit) |
| Net Cash Used in Operating Activities | $(31.1) million | $(11.1) million |
Liquidity: As of March 31, 2026, the Company held $267.8 million in cash and cash equivalents, primarily resulting from a $270.0 million capitalization transfer from the Former Parent during the spin-off. Management believes this is sufficient to fund operations for at least 12 months.
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased by $18.1 million (1,150%) year-over-year. This was driven primarily by the recognition of a $15.0 million milestone payment from Bristol Myers Squibb (BMS) for the successful delivery of a development candidate.
- Expense Increase: Total operating expenses rose by $27.9 million. Research and Development (R&D) expenses increased by $9.7 million due to higher external contract manufacturing costs and internal personnel costs. General and Administrative (G&A) expenses increased by $18.2 million, largely due to accelerated stock-based compensation vesting related to the spin-off and costs associated with establishing independent public company infrastructure.
- Stock-Based Compensation: Total stock-based compensation expense was $12.2 million in Q1 2026 compared to $1.2 million in Q1 2025, reflecting the spin-off transition.
- Balance Sheet Transformation: The Company transitioned from a deficit position within the Former Parent to a standalone equity position of $234.1 million, with total assets increasing from $8.4 million to $292.4 million.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- ATR 1072: Lead candidate for PRKAG2 syndrome. The Company expects to file an Investigational New Drug (IND) application in the second half of 2026.
- ATR 1086: Candidate for PLN cardiomyopathy. IND filing is expected in 2027.
- Collaborations: The Company relies on agreements with BMS and Eli Lilly. BMS is responsible for future clinical development of licensed compounds, while the Company funds early research.
Management Commentary:
- The Company is now operating independently and managing its own liquidity, no longer participating in Avidity's centralized treasury system.
- Costs to operate as a standalone public company (legal, accounting, IT, compliance) are expected to increase over time.
Risks and Contingencies:
- Capital Requirements: The Company expects to incur significant losses for the foreseeable future and will require substantial additional financing to advance clinical trials and commercialization.
- Intellectual Property: The Company relies on a license agreement with Avidity (Novartis) for certain platform-related IP. Avidity retains rights to non-cardiology IP and has a right of first negotiation on certain transactions.
- Regulatory Uncertainty: As a pre-clinical company, there is no assurance that product candidates will receive regulatory approval or achieve commercial success.
Investor Verification Checklist
- Spin-Off Accounting: Verify the allocation of expenses and assets from Avidity to ensure the standalone financials accurately reflect future operating costs.
- Cash Runway: Confirm the $267.8 million cash balance is sufficient to reach the planned IND filing for ATR 1072 in late 2026 without immediate dilution.
- BMS Milestone: Review the terms of the BMS Collaboration Agreement to understand the timing and probability of future milestone payments.
- IP License Terms: Examine the Avidity License Agreement for restrictions on future strategic transactions and the scope of the license granted for the RNA delivery platform.
- Stock-Based Compensation: Assess the sustainability of operating expenses given the one-time nature of the accelerated vesting costs incurred in Q1 2026.